Lisata Therapeutics, Inc. LSTA
Lisata Therapeutics, Inc. (Nasdaq: LSTA) is an oncology drug developer. Its lead program, certepetide (LSTA1), is in Phase 2 for metastatic pancreatic ductal adenocarcinoma (mPDAC) and other solid tumors. Its next catalyst on record is certepetide (ASCEND): Final clinical study report (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: certepetide (ASCEND) — Final clinical study report (2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| certepetide | mPDAC (Phase 2b ASCEND, complete; final report pending) | protein/peptide | Phase 2 |
| certepetide | pancreatic and other solid tumors (Phase 2a BOLSTER, complete; investigator-sponsored trials continuing) | protein/peptide | Phase 2 |
Recent results and decisions
- Sep 17, 2026positive Marea investor deck: MAR001 Phase 2b 12-week topline showed ~40% median TG lowering overall, >65% at baseline TG >=400 mg/dL (n=15) and ~70% at TG >=500 mg/dL (n=7), with no HbA1c increase; small subgroups, no placebo-adjusted figures.
~70% in TG≥500 mg/dL group (n=7; MAR001 pooled)
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.